{
    "clinical_study": {
        "@rank": "105765", 
        "arm_group": [
            {
                "arm_group_label": "Saizen\u00ae treatment group", 
                "arm_group_type": "Experimental", 
                "description": "Saizen\u00ae 0.067 mg/kg/day will be given for the duration of 12 months."
            }, 
            {
                "arm_group_label": "Control group", 
                "arm_group_type": "Active Comparator", 
                "description": "For the first 6 months during the study no treatment will be given and for next 6 months Saizen\u00ae 0.067 mg/kg/day will be given."
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open-label, multi-center, randomized, two-arm parallel, no-treatment group\n      controlled (only for the first 6 months), Phase 3 study in children with ISS. The subjects\n      will be treated with 0.067 milligram/kilogram/day (mg/kg/day) of Saizen\u00ae, weight base dose,\n      for 12 months (12 months of treatment in the test group, and 6 months of no treatment and\n      then 6 months of treatment in the control group)."
        }, 
        "brief_title": "A Phase 3 Study to Evaluate the Safety and Efficacy of Saizen\u00ae in Children With Idiopathic Short Stature (ISS)", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Idiopathic Short Stature", 
        "condition_browse": {
            "mesh_term": "Dwarfism"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age greater than or equal to 5 years\n\n          -  Pre-pubertal; testicular volume less than 4 milliliter (in males) and breast Stage 1\n             (in females)\n\n          -  The official records of height (for example records measured in hospitals or schools)\n             during previous 6 months or more preceding inclusion in the study (self-measurement\n             of the height at home will not be considered as a valid record)\n\n          -  Height less than or equal to 3rd percentile compared to same sex, same age\n\n          -  Peak serum growth hormone (GH) greater than 10 microgram per liter (mcg/L) in GH\n             stimulation test (results of peak serum GH greater than 10 mcg/L in GH stimulation\n             test within 1 year can be used instead)\n\n          -  Naive to GH therapy\n\n          -  Normal birth weight (that is greater than or equal to 3rd percentile when compared to\n             same sex)\n\n          -  Normal thyroid function\n\n          -  Normal karyotype in girls\n\n          -  Written informed consent from parent/guardian\n\n          -  Written informed consent from the subject who speaks, understand, read, and write\n             Korean\n\n          -  Bone age less than 10 years in boys and less than 9 years in girls, whose difference\n             between the bone and chronological age is no more than 3 years\n\n        Exclusion Criteria:\n\n          -  Puberty development (Tanner stage greater than or equal to 2)\n\n          -  Skeletal dysplasia or abnormal body proportions\n\n          -  Chronic systemic illness\n\n          -  Dysmorphic syndrome\n\n          -  Growth Hormone Deficiency\n\n          -  Small for Gestational Age (SGA)\n\n          -  Current medication for Attention deficit hyperactivity disorder (ADHD) or\n             hyperactivity disorder\n\n          -  Current medication with drugs that may influence secretion or action of growth\n             hormone (such as estrogen, androgen, anabolic steroid, corticosteroid, thyroxine,\n             aromatase inhibitors)\n\n          -  Diabetes mellitus\n\n          -  Kidney transplantation\n\n          -  Acute critical illness, including complications following open heart surgery,\n             abdominal surgery or multiple accidental trauma\n\n          -  Acute respiratory failure\n\n          -  Malignancy or previous therapy for malignancy\n\n          -  Known hypersensitivity to somatotropin or any of its excipients including cresol or\n             glycerol\n\n          -  Closed epiphyses, progression or recurrence of an underlying intracranial tumor,\n             chronic renal disease\n\n          -  Endocrinologic or metabolic disorders such as Prader-Willi syndrome; Russel-Silver\n             syndrome; Seckel syndrome; Down syndrome; Cushing syndrome; Noonan syndrome; short\n             stature caused by other chromosomal abnormalities\n\n          -  The disorders that explain short stature such as psychiatric disorders, nutritional\n             disorders, and chronic debilitating diseases\n\n          -  Participation in another clinical trial within the past 3 months\n\n          -  Status of legal incapacity or limited legal capacity of the parents or legal guardian"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "5 Years"
        }, 
        "enrollment": {
            "#text": "87", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01746862", 
            "org_study_id": "EMR200104-533"
        }, 
        "intervention": {
            "arm_group_label": [
                "Saizen\u00ae treatment group", 
                "Control group"
            ], 
            "description": "Saizen\u00ae (Recombinant-human growth hormone [r-hGH]) will be administered subcutaneously as 6 days per week at a weight based dose of 0.067 mg/kg/day for 12 months in Saizen\u00ae treatment group and for 6 months in control group.", 
            "intervention_name": "Saizen\u00ae", 
            "intervention_type": "Drug", 
            "other_name": [
                "Somatropin", 
                "r-hGH"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Saizen\u00ae", 
            "Recombinant human growth hormone (r-hGH)", 
            "Idiopathic short stature", 
            "Height velocity", 
            "Bone age"
        ], 
        "lastchanged_date": "February 7, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Located in", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Please contact Merck KGaA Communication Center for Recruting Sites"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open-label, Two-arm Parallel Group, No Treatment Group-controlled, Multicenter Phase III Study to Evaluate the Safety and Efficacy of Saizen\u00ae 0.067 mg/kg/Day Subcutaneous Injection in Children With Idiopathic Short Stature", 
        "overall_contact": {
            "email": "service@merckgroup.com", 
            "last_name": "Merck KGaA Communication Center", 
            "phone": "+49-6151-72-5200"
        }, 
        "overall_official": {
            "affiliation": "Merck Ltd.", 
            "last_name": "Medical Responsible", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Korea: Food and Drug Administration", 
                "Korea: Institutional Review Board"
            ]
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in growth velocity (centimeter/year [cm/yr]) at Month 6", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Month 6"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01746862"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in growth velocity (cm/yr) at Month 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Month 12"
            }, 
            {
                "measure": "Changes from baseline in height (centimeter [cm]) at Month 6 and 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Month 6 and 12"
            }, 
            {
                "measure": "Changes from baseline in height standard deviation score (SDS) at Month 6 and 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Month 6 and 12"
            }, 
            {
                "measure": "Changes from baseline in serum concentration of insulin-like growth factor-I (IGF-I) and insulin like growth factor binding protein-3 (IGFBP-3) at Month 6 and 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Month 3, 6, 9 and 12"
            }, 
            {
                "measure": "Percentage of participants who adhered to study treatment", 
                "safety_issue": "No", 
                "time_frame": "Month 3, 6, 9 and 12"
            }, 
            {
                "measure": "Number of participants with adverse events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline up to Month 13"
            }
        ], 
        "source": "Merck KGaA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck KGaA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}